SuperNova Diagnostics, a US-based privately-held global diagnostics company for human and non-human health applications, has announced that it has signed an agreement with Shenzhen Kang Sheng Bao Bio-Technology, a biotechnology diagnostics company specializing in research, manufacture and distribution of in-vitro diagnostic kits and research reagents in China and affiliated markets for the research, development, manufacture and commercialisation of diagnostic products and services for the measurement of Neopterin, its metabolites and derivatives utilising the SuperNova technology platform of AmpCrystal.
"We are delighted to announce this agreement with KSB Diagnostics, a leader in China and Asia for diagnostics," said Neil Campbell, president and CEO of SuperNova Diagnostics. "This collaborative agreement allows SuperNova and KSB to expand R&D, manufacturing and commercialisation of a proprietary set of biomarkers for acute and chronic inflammatory conditions into one of the world's largest markets initially and then potentially rest of the world.